Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization - Summary - MDSpire

Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization

  • By

  • Meng Hu

  • Nan Zhang

  • Ya-Qi Wang

  • Xiao-Ming Wang

  • Yun Shi

  • Min Yao

  • Lian-Guo Hou

  • Ling-Ling Jiang

  • July 2, 2026

  • 0 min

Share

Objective:

To correct errors in the previously published article regarding GNPAT's role in immune suppression in hepatocellular carcinoma.

Approach:
  • Correction of Figure 3: The correction includes replacing 'PE' with 'plasmalogen PE' in Figure 3E and adjusting the caption from '(A, F)' to '(A). (F)'.
Key Findings:
  • Figure 3E now correctly identifies 'plasmalogen PE'.
  • The caption of Figure 3 has been amended to '(A). (F)'.
Interpretation:

Conclusion:

The original version of the article has been updated to reflect these corrections.

Sources:

Original Source(s)

Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization

  • by Meng Hu, Nan Zhang, Ya-Qi Wang, Xiao-Ming Wang, Yun Shi, Min Yao, Lian-Guo Hou, Ling-Ling Jiang

  • July 2, 2026

Related Content

Preoperative inflammatory and immune-nutritional markers and postoperative pulmonary complications after gastric and colorectal cancer surgery: a systematic review and narrative synthesis

The immunosuppressive tumor microenvironment in glioblastoma

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression